ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,083,098 | +0.1% | 86,321 | -4.6% | 0.01% | 0.0% |
| Q2 2023 | $8,077,303 | -17.8% | 90,502 | -1.3% | 0.01% | -22.2% |
| Q1 2023 | $9,831,324 | -12.2% | 91,693 | +0.0% | 0.01% | -25.0% |
| Q4 2022 | $11,197,122 | +22.5% | 91,682 | +3.6% | 0.01% | +33.3% |
| Q3 2022 | $9,139,000 | +14.6% | 88,497 | +3.1% | 0.01% | +12.5% |
| Q2 2022 | $7,976,000 | -28.2% | 85,800 | -9.4% | 0.01% | 0.0% |
| Q1 2022 | $11,108,000 | -4.1% | 94,651 | +10.0% | 0.01% | +33.3% |
| Q4 2021 | $11,580,000 | -12.9% | 86,072 | +3.2% | 0.01% | -14.3% |
| Q3 2021 | $13,299,000 | +35.6% | 83,434 | +11.9% | 0.01% | +40.0% |
| Q2 2021 | $9,807,000 | -25.6% | 74,552 | -27.1% | 0.01% | -28.6% |
| Q1 2021 | $13,183,000 | +67.6% | 102,294 | +116.9% | 0.01% | +75.0% |
| Q4 2020 | $7,865,000 | – | 47,155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |